Update-2 1/21/19…Heads Up Red Futures Growth worries return-Asian Stocks down IMF Lowers Global Growth-Poor Performance for Europe Biotech rally could stall Update-1 1/20/19…XBI at $83.38 approaching November resistance at $85 Barron’s 2019 Roundtable biopharma picks: Abbvie (ABBV), Roche Holding (ROG), Gilead Sciences (GILD). ======= Biotech Rally Continues from the J.P.Morgan Healthcare Conference Slow and steady […]
Update-2 After close: Market Collapses After FED Meeting-Bear Market WE all knew that the biotech sector likes looser monetary policy but this sell-off is ridiculous. The IBB is now at May 2017 levels! XBI breaks through 2018 technicals down 3.33% on downside to $71.20, now at June 2017 lows. Update-1 1 pm 12/19/18 Green Day […]
Update -4 After Close 12/7/18 Market Performance for the Week XBI down 7.8%, IBB down 6.6%, XLV down 5.2%, QQQ down 5.11%. Futures not looking good at 12:40a EST, NAZ down 0.82%. Global Growth worries mount; geopolitical turmoil reigns. Moderna (MRNA) IPO closes down 19.13% to $18.60: Largest Biotech to Go Public…https://finance.yahoo.com/news/nasdaq-welcomes-moderna-inc-nasdaq-185435974.html ======= Update-3 After […]
Biotech Momentum Lost Technical Breakdown: XBI Near April Bottom but XLV Looks Good Market Looking for Growth from Large Cap Earnings 10 year auction has tepid demand at Yield of 3.225%, NASDAQ at 7602 own 1.75% (Prices as of mid-day 1:30 p EDT) Biotech momentum losses were triggered by a reversal in investor psychology because […]
Update 10/5/18 Very Weak Technicals after Biotech Sell-Off NASDAQ market closed off the lows down 1.16% at 7788. Biotech ETF IBB down 1.15% just above 3 month support of 116. Biotech ETF XBI down 1.51% at 90.45 broke downtrend line and May support at 92. More losers again but a several winners: e.g. BLUE,CRSP,IONS,RHHBY. Our […]
Biotech Weekly Ending 8/18 …Five Day Performance The Biotech sector held on a turbulent geopolitical week favoring large caps. Amgen (AMGN) up 1.7%, Merck (MRK) up 3.6%, Regeneron (REGN) up 2.1%. Gilead Sciences (GILD) was off 6% on concerns it would lose market share of its HIV drug to GlaxoSmith Kline (GSK) up 2.9% for […]
Sell-Off Gets Scary–NASDAQ Futures Still Down at 1:30A EDT 3/28 Double Bottom -Double Top on XBI and Testing February Lows at $87 Another Sell-Off=Tuesday Movers 3/27/18 Large Caps % Up-NONE FBT Down 3.23%, IBB Down 2.77% to $105.12, QQQ down 3.24%, XBI down 4.27% Mid-caps % Up -None ========== BIG RALLY-Monday Movers 3/26/18 FBT Up 2.83%, […]
Update-1… 3/19. Close is off the lows for Biotech Indices QQQ gap down to $167.10 also at SMA 50 XBI at SMA 50 bottom of channel at $91.89 XLV at $84 approaching February lows of $81 It is very difficult to find news or trends that can help us navigate this sell-off where macro […]
Profit Taking Hits Biotech Stocks Disruption Coming to Healthcare? Another Round of Sector Rotation? The biotech sector hit a wall after breaking through to new highs last week. The major news that sparked profit taking on Tuesday was that Amazon, Berkshire Hathaway and J.P.Morgan formed a consortium to address rising healthcare costs by trying to […]
MegaCap Tech Stocks Take a Big Hit-Volatility Rising in a Sector Shift Market Rotation Supports Overall Market-S&P 500 Stable today up 17% YTD Sluggish Biotech Now Just a Market Performer With IBB up 17% YTD The booming tech sector sold off today with the XLK down over 2%. Harder hit were the 2017 high fliers […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.